Pharmaceutical TechnologyOriginal article
EAN 2026: following EU approval, AbbVie highlights Aquipta efficacy for acute migraine
Data ReadoutpositiveAquiptaPositive
AI Analysis
Summary
AbbVie presented Phase III ECLIPSE trial results for Aquipta in acute migraine at the European Academy of Neurology Congress, following EU approval.
Clinical Trial Data
Phase
Phase 3
NCT ID
Outcome Details
Phase III ECLIPSE trial results presented showing efficacy for acute migraine
Importance:6/10
Sentiment:
0.60
migraineneurologyPhase 3EU approvalconference presentation
Related Companies
Read the original article
Published by Pharmaceutical Technology on July 1, 2026 9:09 AM